ArticleLipids in health and disease2014
Risk stratification of patients with familial hypercholesterolemia in a multi-ethnic cohort.
Article in Lipids in health and disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Sex differences in treatment of familial hypercholesterolaemia: a meta-analysis.European heart journal · 2024Pooled it
- Lipoprotein(a) in Japanese Patients With Cardiovascular Disease: A Systematic Review.JACC. Asia · 2025Review
- Screening for Subclinical Atherosclerosis in Patients with Familial Hypercholesterolemia: Insights and Implications.Journal of clinical medicine · 2025Article
- Lipoprotein(a) in children and adolescents with genetically confirmed familial hypercholesterolemia followed up at a specialized lipid clinic.Atherosclerosis plus · 2024Article
- Lipoprotein Metabolism, Dyslipidemia, and Lipid-Lowering Therapy in Women: A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- A Japanese Case of Familial Hypercholesterolemia with a Protein-truncating Variant in LDLR and a PCSK9 Variant without Significant Atherosclerosis but Showing Remarkable Achilles Tendon Thickening.Internal medicine (Tokyo, Japan) · 2024Article
- Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolemia: an expert consensus statement from ERKNet and ESPN.medRxiv : the preprint server for health sciences · 2023Article
- Sex Differences in Familial Hypercholesterolemia.Current atherosclerosis reports · 2023Review
- Women with familial hypercholesterolemia phenotype are undertreated and poorly controlled compared to men.Scientific reports · 2023Article
- Non-genetic influences on lipoprotein(a) concentrations.Atherosclerosis · 2022Review
- Diabetes and Familial Hypercholesterolemia: Interplay between Lipid and Glucose Metabolism.Nutrients · 2022Review
- Article
- Familial Hypercholesterolemia in the Arabian Gulf Region: Clinical results of the Gulf FH Registry.PloS one · 2021Article
- Article
- Lipoprotein(a) and Familial Hypercholesterolemia: A Short Review Including the Laboratory Viewpoint.Cardiology research · 2020Review
- Risk of cardiovascular disease with lipoprotein(a) in familial hypercholesterolemia: a review.Archives of medical sciences. Atherosclerotic diseases · 2020Article
- Clinical and genetic characteristics of familial hypercholesterolemia patients with type 2 diabetes.Journal of endocrinological investigation · 2019Article
- Article
- Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors.European journal of preventive cardiology · 2017Review
- Lipoprotein (a): impact by ethnicity and environmental and medical conditions.Journal of lipid research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeterozygous Familial hypercholesterolemia (FH) is a common autosomal dominant disorder resulting in in very high blood cholesterol levels and premature cardiovascular disease (CVD). However, there is a wide variation in the occurrence of CVD in these patients. The aim of this study is to determine risk factors that are responsible for the variability of CVD events in FH patients.
methodsThis is a retrospective analysis of a large multiethnic cohort of patients with definite FH attending the Healthy Heart Prevention Clinic in Vancouver, Canada. Cox proportional hazard regression analysis was used to assess the association of the risk factors to the hard cardiovascular outcomes.
results409 patients were identified as having "definite" FH, according to the Dutch Lipid Clinic Network Criteria (DLCNC), with 111 (27%) having evidence of CVD. Male sex, family history of premature CVD, diabetes mellitus, low high density lipoprotein cholesterol (HDL-C) and high lipoprotein (a) (Lp (a)) were significant, independent risk factors for CVD. In men, family history, diabetes and low levels of HDL-C were significant risk factors while in women smoking, diabetes mellitus and high Lp (a) were significant risk factors for CVD. There were no significant differences in risk factors between ethnicities.
conclusionIn conclusion, men and women differ in the impact of the risk factors on the presence of CVD with family history of CVD and low HDL-C being a significant factor in men while smoking and increased Lp (a) were significant factors in women. Diabetes was a significant factor in both men and women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.